
EMBECTA CORP
EMBC · NASDAQ
更新於 2026-10-15 10:31:47
- 今日最高
- $6.25
- 今日最低
- $6.11
K線圖趨勢,實際資料以交易頁為準
關鍵數據
- 昨天開盤價
- $6.19
- 昨天收盤價
- $6.18
- 成交量
- 651.46K
- 市值
- $350.15M
- 市盈率(P/E)
- 4.00X
- 每股收益(EPS)
- $1.47
昨天價格區間
52週價格區間
公司概況
- 板塊
- HEALTHCARE
- 行業
- Health Care
- 子行業
- MEDICAL INSTRUMENTS & SUPPLIES
- 總部
- 300 KIMBALL DRIVE, PARSIPPANY, NJ, UNITED STATES, 07054
- 國家
- US
- 上市日期
- 2022-03-21
- 財年截止
- September
- 流通股數
- 59.33M
- CIK
- 0001872789
- 官方網址
- www.embecta.com
Embecta Corp (EMBC) is a leading medical technology company specializing in innovative insulin delivery systems aimed at enhancing diabetes management. Born from a spin-off of Becton, Dickinson and Company, Embecta provides a comprehensive portfolio of advanced products, including cutting-edge insulin pens and syringes tailored to improve patient outcomes. With a robust focus on operational excellence and customer satisfaction, Embecta is well-positioned to capitalize on growth opportunities in the rapidly expanding diabetes care market, strengthening its leadership in this vital sector.
財務指標
營業收入
2026-06-30
$271.7M
2026-03-31
$221.8M
2025-12-31
$261.2M
2025-09-30
$264M
營業支出
2026-06-30
$104.6M
2026-03-31
$82.3M
2025-12-31
$78.5M
2025-09-30
$91.6M
淨利潤
2026-06-30
$21.1M
2026-03-31
-$4.1M
2025-12-31
$44.1M
2025-09-30
$26.4M
淨利潤率
2026-06-30
7.76%
2026-03-31
-1.84%
2025-12-31
16.88%
2025-09-30
10%
每股收益
2026-06-30
$0.56
2026-03-31
$0.27
2025-12-31
$0.71
2025-09-30
$0.50
息稅折舊攤銷前利潤
2026-06-30
$64.7M
2026-03-31
$44.9M
2025-12-31
$95.9M
2025-09-30
$60.4M
有效稅率
2026-06-30
23.55%
2026-03-31
143.15%
2025-12-31
25.12%
2025-09-30
8.96%
| 項目 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| 營業收入 | $271.7M | $221.8M | $261.2M | $264M |
| 營業支出 | $104.6M | $82.3M | $78.5M | $91.6M |
| 淨利潤 | $21.1M | -$4.1M | $44.1M | $26.4M |
| 淨利潤率 | 7.76% | -1.84% | 16.88% | 10% |
| 每股收益 | $0.56 | $0.27 | $0.71 | $0.50 |
| 息稅折舊攤銷前利潤 | $64.7M | $44.9M | $95.9M | $60.4M |
| 有效稅率 | 23.55% | 143.15% | 25.12% | 8.96% |
常見問題
風險提示
股價可能大幅波動,短時間內可能出現顯著漲跌。 數位資產與衍生性商品交易可能涉及槓桿、流動性等額外風險。 本頁內容僅供參考,不構成任何投資建議。 產品可用性與訪問可能因地區及適用法規而異。